iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
P/B ratio for iRhythm Technologies, Inc. (IRTC)
P/B ratio as of 2023: 15.55
According to iRhythm Technologies, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.55. At the end of 2022 the company had a P/B ratio of 11.69.
P/B ratio history for iRhythm Technologies, Inc. from 2013 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 15.55 |
| 2022 | 11.69 |
| 2021 | 12.35 |
| 2020 | 19.27 |
| 2019 | 12.70 |
| 2018 | 30.49 |
| 2017 | 15.94 |
| 2016 | 1.71 |
| 2015 | -3.79 |
| 2014 | -4.78 |
| 2013 | 7.20 |